Equity Profile

CPRX

Catalyst Pharmaceuticals, Inc.

Health CareBiotechnology$3.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.79

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate strong demand for its products and successful market penetration.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in the health care sector, particularly in addressing unmet medical needs for patients with serious conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1-2026, Catalyst Pharmaceuticals reported an EPS of $0.79, exceeding expectations by 36.21%. The stock remained stable the following day, indicating cautious investor sentiment despite the strong earnings.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing rare diseases with innovative therapies.
Plans to enhance market presence and patient access.

Expectations

Wall Street Expectations

Overall expectations for Catalyst Pharmaceuticals are mixed, with a history of beating EPS estimates but uncertainty surrounding revenue figures. Investors are keen to see if the company can maintain its positive momentum.

Bull Case

The optimistic view hinges on the company continuing its streak of earnings surprises, potentially leading to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant pullback in the stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.79

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would indicate strong demand for its products and successful market penetration.

Market Reaction to Earnings

N/A

Understanding how the stock has reacted to past earnings surprises can provide insights into potential future movements.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's strong history of EPS surprises, this figure will be critical in determining investor sentiment and stock performance.

What are the company's revenue projections for the upcoming quarters?

Revenue growth is essential for sustaining the company's market position and will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Catalyst to exceed EPS expectations based on its recent performance history.

Supporting Evidence

The company has consistently beaten EPS estimates, achieving a 100% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that investors are preparing for potential volatility.

The lack of revenue estimates may lead to conservative projections that do not fully capture the company's growth potential.

Key Risk

If the EPS comes in above $0.79, it could challenge the current cautious sentiment and lead to a re-evaluation of the stock's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Catalyst can continue its trend of exceeding earnings expectations.

Bull Confirmed If

An EPS of $0.79 or higher would confirm the bull case, reinforcing investor confidence in the company's growth trajectory.

Bear Confirmed If

An EPS below $0.68 would validate the bear case, raising concerns about the company's ability to maintain profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around +0.67%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around -1.94% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming therapies.
2Management's commentary on market expansion strategies.
3Insights into patient access initiatives and their impact on revenue.
4Details on competitive landscape and how Catalyst plans to differentiate itself.
5Any forward-looking statements regarding revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.79

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate strong demand for its products and successful market penetration.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing rare diseases with innovative therapies.
Plans to enhance market presence and patient access.

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on the company continuing its streak of earnings surprises, potentially leading to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant pullback in the stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.79

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would indicate strong demand for its products and successful market penetration.

Market Reaction to Earnings

N/A

Understanding how the stock has reacted to past earnings surprises can provide insights into potential future movements.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's strong history of EPS surprises, this figure will be critical in determining investor sentiment and stock performance.

What are the company's revenue projections for the upcoming quarters?

Revenue growth is essential for sustaining the company's market position and will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Catalyst to exceed EPS expectations based on its recent performance history.

Supporting Evidence

The company has consistently beaten EPS estimates, achieving a 100% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that investors are preparing for potential volatility.

The lack of revenue estimates may lead to conservative projections that do not fully capture the company's growth potential.

Key Risk

If the EPS comes in above $0.79, it could challenge the current cautious sentiment and lead to a re-evaluation of the stock's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Catalyst can continue its trend of exceeding earnings expectations.

Bull Confirmed If

An EPS of $0.79 or higher would confirm the bull case, reinforcing investor confidence in the company's growth trajectory.

Bear Confirmed If

An EPS below $0.68 would validate the bear case, raising concerns about the company's ability to maintain profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around +0.67%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around -1.94% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming therapies.
2Management's commentary on market expansion strategies.
3Insights into patient access initiatives and their impact on revenue.
4Details on competitive landscape and how Catalyst plans to differentiate itself.
5Any forward-looking statements regarding revenue growth expectations.